MedTrace Logo

Olopatadine Hydrochloride Ophthalmic Solution Study in Chinese Subjects

NCT02322216 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 383

Last updated 2017-11-17

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate olopatadine 0.2% QD (once per day) compared to olopatadine 0.1% BID (twice per day) in the treatment of ocular itching associated with allergic conjunctivitis.

Conditions

  • Allergic Conjunctivitis

Interventions

DRUG

Olopatadine Hydrochloride Ophthalmic Solution 0.2%

DRUG

Olopatadine Hydrochloride Ophthalmic Solution 0.1%

DRUG

Olopatadine 0.2% Vehicle

Inactive ingredients used as placebo comparator

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Principal Investigators

  • Master, Clinical Medicine · Alcon (China) Ophthalmic Product Co., Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2015-10-31
Completion
2015-10-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02322216 on ClinicalTrials.gov